Previous close | 0.3600 |
Open | 0.3500 |
Bid | 0.1800 |
Ask | 0.4500 |
Strike | 45.00 |
Expiry date | 2025-01-17 |
Day's range | 0.3500 - 0.3600 |
Contract range | N/A |
Volume | |
Open interest | 50 |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.